Small intestinal bacterial overgrowth in inactive Crohn's disease: Influence of thiopurine and biological treatment

World Journal of Gastroenterology

Volumn 20, Issue 38, 2014, Pages 13999-14003

  Sánchez Montes, Cristina ^a   Ortiz, Vicente ^a   Bastida, Guillermo ^a   Rodríguez, Ester ^a   Yago, María ^a   Beltrán, Belén ^a   Aguas, Mariam ^a   Iborra, Marisa ^a   Garrigues, Vicente ^a   Ponce, Julio ^a   Nos, Pilar ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Bacterial overgrowth; Biologics; Crohn's disease; Inflammatory bowel disease; Thiopurines

Indexed keywords

AZATHIOPRINE; HYDROGEN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; GASTROINTESTINAL AGENT; PURINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BACTERIAL OVERGROWTH; BIOLOGICAL THERAPY; BREATH ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; METEORISM; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; REMISSION; SMALL INTESTINAL BACTERIAL OVERGROWTH; SMALL INTESTINE DISEASE; UNIVARIATE ANALYSIS; ANTAGONISTS AND INHIBITORS; BACTERIUM; DRUG COMBINATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; PREVALENCE; RISK FACTOR; SMALL INTESTINE; SPAIN; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; BACTERIA; BIOLOGICAL PRODUCTS; BREATH TESTS; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINE, SMALL; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PURINES; REMISSION INDUCTION; RISK FACTORS; SPAIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84910000320     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i38.13999     Document Type: Article

References (17)

1. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-483; quiz 464, 484 [PMID: 19174807 DOI: 10.1038/ajg.2008.168]
2. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G, Travis S, Stange E. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27 [PMID: 21122488 DOI: 10.1016/j.crohns.2009.12.003]
3. Gasbarrini A, Corazza GR, Gasbarrini G, Montalto M, Di Stefano M, Basilisco G, Parodi A, Usai-Satta P, Vernia P, Anania C, Astegiano M, Barbara G, Benini L, Bonazzi P, Capurso G, Certo M, Colecchia A, Cuoco L, Di Sario A, Festi D, Lauritano C, Miceli E, Nardone G, Perri F, Portincasa P, Risicato R, Sorge M, Tursi A. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther 2009; 29 Suppl 1: 1-49 [PMID: 19344474 DOI: 10.1111/j.1365-2036.2009.03951.x]
4. Castiglione F, Del Vecchio Blanco G, Rispo A, Petrelli G, Amalfi G, Cozzolino A, Cuccaro I, Mazzacca G. Orocecal transit time and bacterial overgrowth in patients with Crohn' s disease. J Clin Gastroenterol 2000; 31: 63-66 [PMID: 10914780]
5. Mishkin D, Boston FM, Blank D, Yalovsky M, Mishkin S. The glucose breath test: a diagnostic test for small bowel stricture(s) in Crohn's disease. Dig Dis Sci 2002; 47: 489-494 [PMID: 11911333 DOI: 10.1023/A:1017991313789]
6. Klaus J, Spaniol U, Adler G, Mason RA, Reinshagen M, von Tirpitz C C. Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease. BMC Gastroenterol 2009; 9: 61 [PMID: 19643023 DOI: 10.1186/1471-230X-9-61]
7. Rutgeerts P, Ghoos Y, Vantrappen G, Eyssen H. Ileal dysfunction and bacterial overgrowth in patients with Crohn' s disease. Eur J Clin Invest 1981; 11: 199-206 [PMID: 6791939 DOI: 10.1111/j.1365-2362.1981.tb01841.x]
8. Afif W, Loftus EV. Safety profile of IBD therapeutics: infectious risks. Gastroenterol Clin North Am 2009; 38: 691-709 [PMID: 19913209 DOI: 10.1016/j.gtc.2009.07.005]
9. Reddy JG, Loftus EV. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 2006; 35: 837-855 [PMID: 17129816 DOI: 10.1016/j.gtc.2006.09.008]
10. Toruner M, Loftus EV, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936 [PMID: 18294633 DOI: 10.1053/j.gastro.2008.01.012]
11. Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation. Am J Gastroenterol 2002; 97: 1113-1126 [PMID: 12014715 DOI: 10.1111/j.1572-0241.2002.05664.x]
12. Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Gastroenterol Rep 2003; 5: 365-372 [PMID: 12959716 DOI: 10.1007/s11894-003-0048-0]
13. King CE, Toskes PP. Comparison of the 1-gram [14C]xylose, 10-gram lactulose-H2, and 80-gram glucose-H2 breath tests in patients with small intestine bacterial overgrowth. Gastroenterology 1986; 91: 1447-1451 [PMID: 3770368]
14. Stotzer PO, Kilander AF. Comparison of the 1-gram (14)C-D- xylose breath test and the 50-gram hydrogen glucose breath test for diagnosis of small intestinal bacterial overgrowth. Digestion 2000; 61: 165-171 [PMID: 10773721 DOI: 10.1159/000007753]
15. Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology 1988; 95: 982-988 [PMID: 3410238]
16. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 Suppl A: 5A-36A [PMID: 16151544]
17. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 483-490 [PMID: 23270866 DOI: 10.1016/j.cgh.2012.12.011]